通过代谢综合征患者的合成生物补充剂改善食欲感觉:一项随机对照临床试验
Fatemeh Hosseini1, Mahboube Pourjam1, Soheila Mirzaeian2
1Department of Clinical Nutrition, School of Nutrition and Food Science, Nutrition and Food Security Research Center Isfahan University of Medical Sciences Isfahan Iran.
Food science & nutrition
|July 26, 2024
概括
与Bacillus益生菌和FOS益生菌的协生补充剂没有改善代谢综合征 (MetS) 患者的血糖控制或炎症. 然而,它显著增加了腹感,这表明潜在的食欲调节益处.
科学领域:
- 微生物组研究的研究.
- 代谢健康 代谢健康
- 营养科学 营养科学
背景情况:
- 肠道失调症,代谢综合征 (MetS),炎症和感官知觉之间的新兴联系.
- 关于用于MetS管理的共生菌 (益生菌+益生菌) 的有限研究.
- 需要在MetS.中研究特定的菌株,如Bacillus indicus,Bacillus coagulans和果酸糖 (FOS).
研究的目的:
- 评估同生菌补充剂对成年MetS患者的血糖指数的影响.
- 评估协生菌对MetS患者关键炎症生物标志物的影响.
- 为了确定共生菌对食欲感觉的影响,包括腹感,在MetS患者中.
主要方法:
- 随机,双盲,安慰剂控制的临床试验涉及58名成年MetS患者.
- 干预组每天两次接受共生菌 (Bacillus indicus,Bacillus coagulans,FOS) 治疗,持续8周.
- 安慰剂组接受了安慰剂.安慰剂组接受了安慰剂. 测量了血糖指数,炎症标志物和食欲感觉.
主要成果:
- 与安慰剂相比,在协生组中没有观察到血糖指数或炎症标志物的显著改善 (p > .05).
- 在共生干预组中报告了腹感的统计显著增加.
- 参与者在同生菌或安慰剂组中都没有报告任何不良反应.
结论:
- 八周的协生补充剂并没有有效地改善葡萄糖控制或减少成年人MetS的炎症.
- 协生菌对食欲调节有潜在的积极影响,特别是增加腹感.
- 建议对更长的干预期进行进一步的研究,以探索共生菌对食欲和代谢健康的持续影响.
相关概念视频
Regulation of Food Intake
213
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
213
Taste Buds and Receptors
1.9K
Gustation, or the sense of taste, is intrinsically linked to the anatomical structures located on the tongue. This organ's surface, along with the entirety of the oral cavity, is adorned with stratified squamous epithelium. Evident on the tongue are elevated structures known as papillae (singular = papilla), which house the mechanisms for the transduction of gustatory stimuli. Four distinct types of papillae exist, each identified by their unique morphological attributes: the circumvallate,...
1.9K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Constipation-Predominant IBS
152
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
152
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
What is Monogastric Digestion?
71.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
71.0K


